Physician profile
Gema Ramos
NPI 1588978365
$2,444.61
in general payments reported to CMS, 2019-2025
14 companies · $1,614 in 2025
The $1,614 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $831 · 2025: $1,614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,444.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $489.32 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $347.98 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $339.55 | 2024-2025 | |
| Lilly USA, LLC | $275.67 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $262.94 | 2024-2025 | Repatha, Repatha, Krystexxa |
| Abbott Laboratories | $170.18 | 2024-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $129.67 | 2024-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $118.00 | 2024-2025 | Farxiga |
| Exact Sciences Corporation | $90.56 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $63.61 | 2025 | Gvoke Hypopen |
| Dexcom, INC. | $48.78 | 2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $47.01 | 2024 | Veozah |
| Kowa Pharmaceuticals America, INC. | $46.32 | 2025 | Zoryve |
| Cranial Technologies, INC | $15.02 | 2024 | Doc Band |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gema Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.